

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

ACADIA PHARMACEUTICALS INC.,	)	
	)	
Plaintiff,	)	
	)	
v.	)	C.A. No. 20-986-RGA
	)	
TEVA PHARMACEUTICALS USA, INC.,	)	
and TEVA PHARMACEUTICAL	)	
INDUSTRIES LTD.,	)	
	)	
Defendants.	)	

**STIPULATION OF DISMISSAL OF COMPLAINT AS TO DEFENDANT TEVA  
PHARMACEUTICAL INDUSTRIES LTD. AND AMENDMENT OF CAPTION**

Plaintiff Acadia Pharmaceuticals (“Acadia” or “Plaintiff”) and Defendants Teva Pharmaceuticals USA, Inc. (“Teva USA”) and Teva Pharmaceutical Industries Limited (“Teva Ltd.”) hereby stipulate, subject to approval of the Court, to dismiss the Complaint filed by Plaintiff against Teva Ltd. in the above-captioned action (“Action”) pursuant to Fed. R. Civ. P. 41(a)(1)(A)(i) and (ii). The Action will continue against Teva USA. The parties further stipulate that this dismissal is without prejudice and is subject to the following conditions:

1. Without conceding that it is a proper party to this litigation, Teva Ltd. stipulates to be bound by any Judgment, Order, or decision in this Action, or any appeal thereof.
2. Defendants stipulate that all of Teva Ltd.’s documents, witnesses, and information are in Teva USA’s possession, custody, and control for purposes of this lawsuit, subject to Paragraph 4. To be clear, Teva Ltd. agrees that it will search for and provide discovery in response to discovery requests and deposition notices served on Teva USA in the Action as if the discovery were Teva USA’s own, subject to any objections, privilege

assertions, or other grounds to oppose discovery pursuant to FRCP or rules or orders of this Court.

3. Pursuant to paragraph 2 above, Defendants agree that any discovery requests directed to Teva USA, including Deposition Notices, Production Requests, Admission Requests, and Interrogatories, will be understood and interpreted as seeking discovery from Teva USA and Teva Ltd. Teva USA will respond to discovery requests for information in the possession, custody, or control of Teva USA and Teva Ltd., including requests for deposition testimony, and will not raise issues of documents or witnesses being in the possession, custody, or control of only Teva Ltd. as a basis for not producing them.

4. If the parties agree that a Teva Ltd. employee is a necessary fact witness, the witness will be made available for deposition in the United States, subject to any governmental travel restrictions due to the COVID-19 global pandemic or other health-related travel restrictions that may exist for any particular witness, upon notice to Teva USA without the need for: (a) service of a subpoena; or (b) if the witness is located outside of the United States, adherence to the procedures of the Hague Convention or other methods of foreign service/discovery. Teva USA will accept Rule 30(b)(6) deposition notices containing topics directed to information that may be held by Teva Ltd., and the witness presented in response thereto shall investigate information in the possession, custody, or control of Teva Ltd. if necessary to prepare for the noticed topics. If the parties disagree as to whether the Teva Ltd. employee is a necessary fact witness, then the parties shall present the matter to the Court for resolution. Teva USA will not use as a basis for objecting to any deposition notice served by Plaintiff the fact that: (i) an individual is an employee of Teva Ltd.; (ii) Teva Ltd. is not a party to this Action; (iii) Plaintiff failed to serve a third-party subpoena for the noticed individual or

entity; (iv) Plaintiff failed to adhere to the procedures of the Hague Convention or other methods of foreign service/discovery; or (v) the Court lacks personal jurisdiction over Teva Ltd. subject to the provisions of paragraph 7 below. In the event that the Court orders that the deposition of the Teva Ltd. employee shall be taken, then the Teva Ltd. employee will be made available for deposition in the United States, subject to any governmental travel restrictions due to the COVID-19 global pandemic or other health-related travel restrictions that may exist for any particular witness, pursuant to the Court's Order without requiring that Plaintiff adhere to the procedures of the Hague Convention or other methods of foreign service/discovery.

5. None of the foregoing shall be interpreted to limit Plaintiff's rights to discovery of Teva Ltd. or Teva USA.

6. This Stipulation and Order does not constitute a waiver of any objection or defense to, or any privilege or immunity from, the provision of discovery otherwise available to parties to an Action under the Federal Rules of Civil Procedure, the Federal Rules of Evidence, or any other applicable authority.

7. The Court retains jurisdiction over Teva Ltd. for the limited purpose of enforcing the terms of this Stipulation and Order and to adjudicate or resolve any disputes regarding its terms, interpretation, application, or requirements. Except as otherwise provided in this Stipulation and Order, Teva Ltd. does not waive and expressly retains its right to argue that the Court lacks personal jurisdiction over Teva Ltd.

8. The case caption should be amended to read: "Acadia Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., Civil Action No. 1:20-cv-00986," as follows:

ACADIA PHARMACEUTICALS INC.,

Plaintiff,

v.

TEVA PHARMACEUTICALS USA, INC.,

Defendant.

Civil Action No. 1:20-cv-00986

s/ James D. Taylor, Jr.

James D. Taylor, Jr. (#4009)  
Jessica M. Jones (#6246)  
Charles E. Davis (#6402)  
SAUL EWING ARNSTEIN & LEIR LLP  
1201 N. Market Street, Suite 2300  
P.O. Box 1266  
Wilmington, DE 19899  
(302) 421-6800  
James.Taylor@saul.com  
Jessica.Jones@saul.com  
Chad.Davis@saul.com

OF COUNSEL:

Chad J. Peterman  
Bruce M. Wexler  
Scott F. Peachman  
PAUL HASTINGS LLP  
200 Park Avenue New York, New York 10166  
(212) 318-6000 chadpeterman@paulhastings.com  
brucewexler@paulhastings.com  
scottpeachman@paulhastings.com

*Attorneys for Plaintiff  
Acadia Pharmaceuticals Inc.*

Dated: August 4, 2020

/s/ Karen E. Keller

John W. Shaw (No. 3362)  
Karen E. Keller (No. 4489)  
Nathan Hoeschen (No. 6232)  
SHAW KELLER LLP  
I.M. Pei Building  
1105 North Market Street, 12th Floor  
Wilmington, DE 19801  
(302) 298-0700  
jshaw@shawkeller.com  
kkeller@shawkeller.com  
nhoeschen@shawkeller.com

OF COUNSEL:

Michael K. Nutter  
Ivan M. Poullaos  
WINSTON & STRAWN LLP  
35 W. Wacker Drive  
Chicago, IL 60601-9703  
(312) 558-5600  
mnutter@winston.com  
ipoullaos@winston.com

*Attorneys for Defendants  
Teva Pharmaceuticals USA, Inc. and  
Teva Pharmaceuticals Industries Ltd.*

**IT IS SO ORDERED** this 4 day of August, 2020:

/s/ Richard G. Andrews  
United States District Judge